Recently, Grandma Sun, an 80-year-old woman suffering from acute lymphoblastic leukemia, went to the Department of Hematology of the Second Affiliated Hospital of Anyi University for a review as scheduled. The examination report showed that the elderly woman’s condition continues to be in remission. Since trying the CAR-T cell clinical trial treatment being carried out by the Department of Hematology at the Second Affiliated Hospital of Anyi University in 2016, Grandma Sun’s physical condition has continued to improve, and she has lived without recurrence for more than 7 years.
The elderly suffer from leukemia and there is no medicine available
In 2013, Grandma Sun was unfortunately diagnosed with acute B lymphoblastic leukemia. After routine chemotherapy, her condition was controlled to a certain extent, but she has been in a recurring state. In 2016, Grandma Sun’s condition relapsed and her body was very weak. Continuing chemotherapy not only failed to effectively control the disease, but also became intolerable for the frail elderly. “The old man was relatively old at the time, and his health was very weak. In that situation, there was basically no medicine available.” According to Professor Zhai Zhimin, director of the Department of Hematology at the Second Affiliated Hospital of An Medical University and a famous doctor in Jianghuai, the Department of Hematology was developing CAR-T at that time. Cell clinical trial treatment, consider using this new technology to give Grandma Sun the last glimmer of hope for life.
CAR-T cells show their effectiveness and the disease has not relapsed in 7 years
After obtaining the consent of the patient’s family, the hematology treatment team decided to implement CAR-T cell targeted immunotherapy for Grandma Sun. Taking into account Grandma Sun’s advanced age and poor physical condition, under the leadership of Professor Zhai Zhimin, the treatment team formulated a detailed treatment plan for Grandma Sun, and the old man’s condition gradually eased as the treatment progressed. In November 2023, the old man came to the hospital for follow-up consultation according to the doctor’s instructions. His physical condition was very good. The old man had not relapsed for more than 7 years. CAR-T cell therapy created a miracle of life.
In the past 10 years, I have devoted myself to research and brought good news to more than 100 patients.
According to Zhai Zhimin, the Department of Hematology of the Second Affiliated Hospital of Anyi University has been committed to the research and development and clinical application of CAR-T cells since the launch of CAR-T cell targeted immunotherapy research in 2014, and has continuously made new breakthroughs in the treatment of relapsed and refractory leukemia. , this emerging technology at the time has been clinically promoted and applied in the past ten years and has successfully treated more than 100 patients with hematological tumors. It is highly safe and has given hope to many terminally ill patients.
It is understood that the indications for CAR-T cell targeted immunotherapy cover almost all blood tumors, including leukemia, lymphoma and myeloma. In 2019, after receiving funding and support from Anhui Province’s major scientific and technological projects, the Department of Hematology of the hospital finally successfully created CAR-T cells targeting the Ex02 target after more than three years of repeated attempts and explorations day and night. This is a brand-new The target has also opened up more clinical application treatments for hematological tumors, bringing good news to more patients. In the first half of this year, the hospital used this new target to successfully treat a patient with advanced myeloma who relapsed after transplantation using CAR-T cell immunotherapy. Zhai Zhimin said that the Department of Hematology of the Second Affiliated Hospital of Anyi University is still continuing to carry out multiple types of CAR-T cell clinical experimental treatment research, hoping to benefit more patients with hematological tumors and benefit more patients. (Second Affiliated Hospital of Anyi University)